Cited by 210Cancer Immunotherapy and BiomarkersGenetic factors in colorectal cancerColorectal Cancer Treatments and Studies

The DOI matches its Crossref record; 14 of the 15 references it cites were found in a registry or an index.

Response to PD-1 Blockade in Microsatellite Stable Metastatic Colorectal Cancer Harboring a POLE Mutation

Open access

Gong, Jun, Wang, Chongkai, Lee, Peter P., Chu, Peiguo, Fakih, Marwan·2017·Journal of the National Comprehensive Cancer Network

DOI 10.6004/jnccn.2017.0016

Open this paper in CoChat — free account Open PDF

Abstract

Recent clinical evidence has demonstrated that microsatellite instability (MSI) or defective mismatch repair (MMR) and high tumor mutational load can predict response to the programmed cell death 1 (PD-1) receptor inhibitor pembrolizumab in metastatic colorectal cancer (mCRC). Mutations in polymerase ε (POLE), a DNA polymerase involved in DNA replication and repair, contribute to an ultramutated but microsatellite stable (MSS) phenotype in colorectal tumors that is uniquely distinct from MSI tumors. This report presents the first case in the literature describing a clinical response to pembrolizumab in an 81-year-old man with treatment-refractory mCRC characterized by an MSS phenotype and POLE mutation identified on genomic profiling by next-generation sequencing. On tumor immunostaining, a large amount of CD8-positive tumor infiltrating lymphocytes (TILs) were present, with >90% of these expressing PD-1. More than 99% of PD-L1 expression was identified on nontumor cells in the tumor microenvironment that were close to the PD-1–positive CD8 TILs. mCRC tumors harboring POLE mutations represent a hypermutated phenotype that may predict response to anti–PD-1 therapy.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.6004/jnccn.2017.0016

Cites

14 of 14 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

The vigorous immune microenvironment of microsatellite instable colon cancer is balanced by multiple counter-inhibitory checkpoints
Llosa, N. J., Cruise, M., Tam, A., Wicks, E. C., Hechenbleikner, E. M., Taube, J. M., Blosser, R. L., Fan, H., Wang, H., Luber, B. S., et al. (2015) · Cancer Discovery · doi:10.1158/2159-8290.cd-14-0863 · Cited by 1,487
Germline mutations affecting the proofreading domains of POLE and POLD1 predispose to colorectal adenomas and carcinomas
Palles, C., Cazier, J., Howarth, K. M., Domingo, E., Jones, A. M., Broderick, P., Kemp, Z., Spain, S. L., Guarino, E., Salguero, I., et al. (2012) · Nature Genetics · doi:10.1038/ng.2503 · Cited by 1,008
Association of Polymerase e–Mutated and Microsatellite-Instable Endometrial Cancers With Neoantigen Load, Number of Tumor-Infiltrating Lymphocytes, and Expression of PD-1 and PD-L1
Howitt, B. E., Shukla, S. A., Sholl, L. M., Ritterhouse, L. L., Watkins, J. C., Rodig, S. J., Stover, E. H., Strickland, K. C., D’Andrea, A. D., Wu, C. J., et al. (2015) · JAMA Oncology · doi:10.1001/jamaoncol.2015.2151 · Cited by 695
PD-1 blockade in tumors with mismatch repair deficiency.
Le, D. T., Uram, J. N., Wang, H., Bartlett, B. R., Kemberling, H., Eyring, A. D., Skora, A. D., Azad, N. S., Laheru, D. A., Donehower, R. C., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.33.15_suppl.lba100 · Cited by 565
Immune activation and response to pembrolizumab in POLE-mutant endometrial cancer
Mehnert, J. M., Panda, A., Zhong, J., Hirshfield, K. M., Damare, S., Lane, K., Sokol, L. O., Stein, M. N., Rodriguez-Rodriquez, L., Kaufman, H. L., et al. (2016) · Journal of Clinical Investigation · doi:10.1172/jci84940 · Cited by 376
Somatic POLE proofreading domain mutation, immune response, and prognosis in colorectal cancer: A retrospective, pooled biomarker study
Domingo, E., Freeman-Mills, L., Rayner, E., Glaire, M., Briggs, S., Vermeulen, L., Fessler, E., Medema, J. P., Boot, A., Morreau, H., et al. (2016) · The Lancet Gastroenterology & Hepatology · doi:10.1016/s2468-1253(16)30014-0 · Cited by 308
Comprehensive molecular characterization of human colon and rectal cancer
McCullough, A. J. (2013) · Yearbook of Pathology and Laboratory Medicine · doi:10.1016/j.ypat.2012.11.050 · Cited by 261
Reliable Detection of Mismatch Repair Deficiency in Colorectal Cancers Using Mutational Load in Next-Generation Sequencing Panels
Stadler, Z. K., Battaglin, F., Middha, S., Hechtman, J. F., Tran, C., Cercek, A., Yaeger, R. D., Segal, N. H., Varghese, A. M., Reidy‐Lagunes, D. L., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.65.1067 · Cited by 238
Mutational profiling of colorectal cancers with microsatellite instability
Lin, E. I., Tseng, L., Gocke, C. D., Reil, S., Le, D. T., Azad, N. S., & Eshleman, J. R. (2015) · Oncotarget · doi:10.18632/oncotarget.5997 · Cited by 95
RAS and BRAF in metastatic colorectal cancer management
Gong, J., Cho, M. T., & Fakih, M. (2016) · Journal of Gastrointestinal Oncology · doi:10.21037/jgo.2016.06.12 · Cited by 84
Self-citation

Flagged first, then by citations

Show all 15 references

1 of the 15 references couldn’t be matched to a known paper.

Research works printed but not linked: 9

Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin 2016;66:7-30.
Briggs S, Tomlinson I. Germline and somatic polymerase ε and δ mutations define a new class of hypermutated colorectal and endometrial cancers. J Pathol 2013;230:148-153.
Kothari N, Teer JK, Abbott AM, et al. Increased incidence of FBXW7 and POLE proofreading domain mutations in young adult colorectal cancers. Cancer 2016;122:2828-2835.
Bellone S, Centritto F, Black J, et al. Polymerase ε (POLE) ultra-mutated tumors induce robust tumor-specific CD4+ T cell responses in endometrial cancer patients. Gynecol Oncol 2015;138:11-17.
van Gool IC, Eggink FA, Freeman-Mills L, et al. POLE proofreading mutations elicit an antitumor immune response in endometrial cancer. Clin Cancer Res 2015;21:3347-3355.
Rizvi NA, Hellmann MD, Snyder A, et al. Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science 2015;348:124-128.
Santin AD, Bellone S, Buza N, et al. Regression of chemotherapy-resistant polymerase epsilon (POLE) ultra-mutated and MSH6 hyper-mutated endometrial tumors with nivolumab. Clin Cancer Res 2016;22:5682-5687.
Jones S, Emmerson P, Maynard J, et al. Biallelic germline mutations in MYH predispose to multiple colorectal adenoma and somatic G:C-->T:A mutations. Hum Mol Genet 2002;11:2961-2967.
Markowitz S, Wang J, Myeroff L, et al. Inactivation of the type II TGF- beta receptor in colon cancer cells with microsatellite instability. Science 1995;268:1336-1338.

Sorted by citations

Items 101–200 of 210

Polymerase Epsilon-Associated Ultramutagenesis in Cancer
Xing, X., Jin, N. Y., & Wang, J. (2022) · Cancers · doi:10.3390/cancers14061467 · Cited by 24
Genomic Alterations of NTRK, POLE, ERBB2, and Microsatellite Instability Status in Chinese Patients with Colorectal Cancer
Guo, Y., Guo, X., Wang, S., Chen, X., Shi, J., Wang, J., Wang, K., Klempner, S. J., Wang, W., & Xiao, M. (2020) · The Oncologist · doi:10.1634/theoncologist.2020-0356 · Cited by 24
Tumor-Infiltrating Immune Cells in Colorectal Cancer
Ferkel, S. A. M., Holman, E. A., Sojwal, R. S., Rubin, S. J. S., & Rogalla, S. (2024) · Neoplasia · doi:10.1016/j.neo.2024.101091 · Cited by 27
New biomarkers for checkpoint inhibitor therapy
Burdett, N. L., & Desai, J. (2020) · ESMO Open · doi:10.1136/esmoopen-2019-000597 · Cited by 23
The Evolving Role of Consensus Molecular Subtypes: a Step Beyond Inpatient Selection for Treatment of Colorectal Cancer
Ros, J., Baraibar, I., Martini, G., Salvà, F., Gonzalez, N. S., Cuadra‐Urteaga, J. L., Dienstmann, R., Tabernero, J. M., & Élez, E. (2021) · Current Treatment Options in Oncology · doi:10.1007/s11864-021-00913-5 · Cited by 22
The PD ‐1 expressing immune phenotype of T cell exhaustion is prominent in the ‘immunoreactive’ microenvironment of colorectal carcinoma
Prall, F., & Hühns, M. (2017) · Histopathology · doi:10.1111/his.13231 · Cited by 22
Immunotherapy in colorectal cancer: is the long-awaited revolution finally happening?
Arrichiello, G., Poliero, L., Borrelli, C., Paragliola, F., Nacca, V., Napolitano, S., Corte, C. M. D., Martini, G., & Martinelli, E. (2021) · Cancer Treatment and Research Communications · doi:10.1016/j.ctarc.2021.100442 · Cited by 20
BRCA1 mRNA expression modifies the effect of T cell activation score on patient survival in breast cancer
Lu, L., Huang, H., Zhou, J., Ma, W., Mackay, S., & Wang, Z. (2019) · BMC Cancer · doi:10.1186/s12885-019-5595-3 · Cited by 21
Progress of Immune Checkpoint Inhibitors Therapy for pMMR/MSS Metastatic Colorectal Cancer
Qu, F., Wu, S., & Yu, W. (2024) · OncoTargets and Therapy · doi:10.2147/ott.s500281 · Cited by 20
Recent Advances in Personalized Cancer Immunotherapy with Immune Checkpoint Inhibitors, T Cells and Vaccines
Faghfuri, E. (2023) · Personalized Medicine · doi:10.2217/pme-2023-0054 · Cited by 20
Research progress and clinical application of predictive biomarker for immune checkpoint inhibitors
Ma, K., Jin, Q., Wang, M., Li, X., & Zhang, Y. (2019) · Expert Review of Molecular Diagnostics · doi:10.1080/14737159.2019.1617702 · Cited by 20
Targeting the spectrum of immune checkpoints in prostate cancer
Sena, L. A., Denmeade, S. R., & Antonarakis, E. S. (2021) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2021.1949287 · Cited by 19
Assessment of POLE and POLD1 mutations as prognosis and immunotherapy biomarkers for stomach adenocarcinoma
Zhu, M., Cui, H., Zhang, L., Zhao, K., Jia, X., & Jin, H. (2021) · Translational Cancer Research · doi:10.21037/tcr-21-1601 · Cited by 19
Immunotherapy in hepatocellular carcinoma: an overview of immune checkpoint inhibitors, drug resistance, and adverse effects
Gu, X.-Y., Huo, J.-L., Yu, Z., Jiang, J.-C., Xu, Y.-X., & Zhao, L. (2024) · ONCOLOGIE · doi:10.1515/oncologie-2023-0412 · Cited by 19
The evolving paradigm of biomarker actionability: Histology-agnosticism as a spectrum, rather than a binary quality
Tarantino, P., Mazzarella, L., Marra, A., Trapani, D., & Curigliano, G. (2021) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2021.102169 · Cited by 18
An immune-related gene prognostic index for predicting prognosis in patients with colorectal cancer
Li, C., Wirth, U., Schardey, J., von Ehrlich-Treuenstätt, V., Bazhin, A. V., Werner, J., & Kühn, F. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1156488 · Cited by 17
Immunologic Biomarkers and Biomarkers for Immunotherapies in Gastrointestinal Cancer
Martin, B., & Märkl, B. (2019) · Visceral Medicine · doi:10.1159/000496565 · Cited by 17
CD8+ tumor‐infiltrating lymphocytes within the primary tumor of patients with synchronous de novo metastatic colorectal carcinoma do not track with survival
Millen, R., Hendry, S. A., Narasimhan, V., Abbott, R. C., Croxford, M. A., Gibbs, P., Tie, J., Wong, H., Jones, I. T., Kosmider, S., et al. (2020) · Clinical & Translational Immunology · doi:10.1002/cti2.1155 · Cited by 17
Complete Response to Pembrolizumab in Advanced Colon Cancer Harboring Somatic POLE F367S Mutation with Microsatellite Stability Status: A Case Study
Chen, J., & Lou, H. (2021) · OncoTargets and Therapy · doi:10.2147/ott.s300987 · Cited by 17
POLE-mutated clear cell cervical cancer associated with in-utero diethylstilbestrol exposure
Lee, E. K., Lindeman, N. I., Matulonis, U. A., & Konstantinopoulos, P. A. (2019) · Gynecologic Oncology Reports · doi:10.1016/j.gore.2019.01.012 · Cited by 16
Towards a precision immune checkpoint blockade immunotherapy in patients with colorectal cancer: Strategies and perspectives
Cui, G. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2022.112923 · Cited by 15
Classification of tumor microenvironment immune types based on immune response-associated gene expression
Kondou, R., Iizuka, A., Nonomura, C., Miyata, H., Ashizawa, T., Nagashima, T., Ohshima, K., Urakami, K., Kusuhara, M., Yamaguchi, K., et al. (2018) · International Journal of Oncology · doi:10.3892/ijo.2018.4617 · Cited by 15
Immunotherapy for Early Stage Colorectal Cancer: A Glance into the Future
Cohen, R., Shi, Q., & André, T. (2020) · Cancers · doi:10.3390/cancers12071990 · Cited by 18
Biomarkers for immune checkpoint therapy targeting programmed death 1 and programmed death ligand 1
Fan, J., Shen, X., Wang, Y., Zhou, H., Liu, G., Li, Y., & Xu, Z. (2020) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2020.110621 · Cited by 15
Whole-exome sequencing analysis of NSCLC reveals the pathogenic missense variants from cancer-associated genes
Kumar, S. U., Balasundaram, A., Hephzibah Cathryn, R., Varghese, R. P., Ramamoorthy, S., Ramanathan, G., Younes, S. N., Zayed, H., & Doss, C. G. P. (2022) · Computers in Biology and Medicine · doi:10.1016/j.compbiomed.2022.105701 · Cited by 15
POLE and POLD1 germline exonuclease domain pathogenic variants, a rare event in colorectal cancer from the Middle East
Siraj, A. K., Bu, R., Iqbal, K., Parvathareddy, S. K., Masoodi, T., Siraj, N., Al-Rasheed, M. M., Kong, Y., Ahmed, S. O., Al‐Obaisi, K. A. S., et al. (2020) · Molecular Genetics & Genomic Medicine · doi:10.1002/mgg3.1368 · Cited by 15
Update on the role of pembrolizumab in patients with unresectable or metastatic colorectal cancer
Wookey, V., & Grothey, A. F. (2021) · Therapeutic Advances in Gastroenterology · doi:10.1177/17562848211024460 · Cited by 16
Association between baseline C‑reactive protein level and survival outcomes for cancer patients treated with immunotherapy: A meta‑analysis
Xu, Y., Ma, K., Zhang, F., Ma, M., Hong, L., Wang, J., Li, S., Sun, P., Wang, J., & Wei, S. (2023) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2023.12060 · Cited by 14
Improving the efficiency of immune checkpoint inhibitors for metastatic pMMR/MSS colorectal cancer: Options and strategies
Yang, C., Zhao, L., Lin, Y., Wang, S., Ye, Y., & Shen, Z. (2023) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2023.104204 · Cited by 16
Genomics-Enabled Precision Medicine for Cancer
Roos, A., & Byron, S. A. (2019) · Cancer treatment and research · doi:10.1007/978-3-030-16391-4_5 · Cited by 14
Molecular correlates of immune cytolytic subgroups in colorectal cancer by integrated genomics analysis
Roufas, C., Georgakopoulos‐Soares, I., & Zaravinos, A. (2021) · NAR Cancer · doi:10.1093/narcan/zcab005 · Cited by 14
Non-Exonuclease Domain POLE Mutations Associated with Immunotherapy Benefit
Dong, S., Zakaria, H., & Hsiehchen, D. (2022) · The Oncologist · doi:10.1093/oncolo/oyac017 · Cited by 14
Immunotherapy for a POLE Mutation Advanced Non-Small-Cell Lung Cancer Patient
Fu, Y., Zheng, Y., Wang, P., Chen, Y., & Ding, Z. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.817265 · Cited by 14
POLE-Mutant Colon Cancer Treated with PD-1 Blockade Showing Clearance of Circulating Tumor DNA and Prolonged Disease-Free Interval
Bikhchandani, M., Amersi, F. F., Hendifar, A. E., Gangi, A., Osipov, A., Zaghiyan, K. N., Atkins, K. M., Cho, M. T., Aguirre, F. P., Hazelett, D. J., et al. (2023) · Genes · doi:10.3390/genes14051054 · Cited by 14
Self-citation
Circular RNA circNCOA3 promotes tumor progression and anti-PD-1 resistance in colorectal cancer
Chen, D., Chen, N., Sheng, H., & Zhang, D. (2024) · Cancer Drug Resistance · doi:10.20517/cdr.2023.151 · Cited by 12
Durable complete response to pembrolizumab in microsatellite stable colorectal cancer
Gomar, M., Najafi, M., Aghili, M., Cozzi, S., & Jahanbakhshi, A. (2021) · DARU Journal of Pharmaceutical Sciences · doi:10.1007/s40199-021-00404-w · Cited by 12
Strategic enhancement of immune checkpoint inhibition in refractory Colorectal Cancer: Trends and future prospective
Liu, N., Shan, F., & Ma, M. (2021) · International Immunopharmacology · doi:10.1016/j.intimp.2021.108017 · Cited by 13
Homologous Recombination Repair Truncations Predict Hypermutation in Microsatellite Stable Colorectal and Endometrial Tumors
Lee, M., Eng, G. M., Barbari, S. R., Deshpande, V., Shcherbakova, P. V., & Gala, M. K. (2020) · Clinical and Translational Gastroenterology · doi:10.14309/ctg.0000000000000149 · Cited by 12
A Detailed Flow Cytometric Analysis of Immune Activity Profiles in Molecular Subtypes of Colorectal Cancer
Li, X., Ling, A., Kellgren, T. G., Lundholm, M., Löfgren‐Burström, A., Zingmark, C., Rutegård, M., Ljuslinder, I., Palmqvist, R., & Edin, S. (2020) · Cancers · doi:10.3390/cancers12113440 · Cited by 12
Enhanced polymerase activity permits efficient synthesis by cancer-associated DNA polymerase ϵ variants at low dNTP levels
Barbari, S. R., Beach, A. K., Markgren, J. G., Parkash, V., Moore, E. A., Johansson, E., & Shcherbakova, P. V. (2022) · Nucleic Acids Research · doi:10.1093/nar/gkac602 · Cited by 11
Four-Year Disease-Free Remission in a Patient With POLE Mutation–Associated Colorectal Cancer Treated Using Anti–PD-1 Therapy
Durando, M., Menghani, S. V., Baumann, J. L., Robles, D. G., Day, T. A., Vaziri, C., & Scott, A. J. (2022) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2021.7115 · Cited by 10
The Emergence of Immune-checkpoint Inhibitors in Colorectal Cancer Therapy
Ghidini, M., Fusco, N., Salati, M., Khakoo, S. S., Tomasello, G., Petrelli, F., Trapani, D., & Petrillo, A. (2021) · Current Drug Targets · doi:10.2174/1389450122666210204204415 · Cited by 10
High Expression of Casein Kinase 2 Alpha Is Responsible for Enhanced Phosphorylation of DNA Mismatch Repair Protein MLH1 and Increased Tumor Mutation Rates in Colorectal Cancer
Ulreich, K., Firnau, M.-B., Tagscherer, N., Beyer, S., Ackermann, A., Plotz, G., & Brieger, A. (2022) · Cancers · doi:10.3390/cancers14061553 · Cited by 10
Immune-related deubiquitylation spectrum of microsatellite stability colorectal cancer reveals USP7 as a potential immunotherapeutic target
Yin, X., Wu, J., Xu, M., Tian, T., Zhu, L., Wang, J., Dai, X., Yang, X., Qian, J., Wang, W., et al. (2025) · Molecular Cancer · doi:10.1186/s12943-025-02502-8 · Cited by 9
Mutation analysis of POLE gene in patients with early-onset colorectal cancer revealed a rare silent variant within the endonuclease domain with potential effect on splicing
Lasabová, Z., Kalman, M., Holubeková, V., Grendár, M., Kašubová, I., Jašek, K., Meršaková, S., Malicherová, B., Baranenko, D., Adamek, M., et al. (2019) · Clinical and Experimental Medicine · doi:10.1007/s10238-019-00558-7 · Cited by 9
Hepatocellular carcinoma (HCC) immunotherapy by anti-PD-1 monoclonal antibodies: A rapidly evolving strategy
Nikoo, M., Hassan, Z. F., Mardasi, M., Rostamnezhad, E., Roozbahani, F., Rahimi, S., & Mohammadi, J. (2023) · Pathology - Research and Practice · doi:10.1016/j.prp.2023.154473 · Cited by 9
FFCD 1709-SIRTCI phase II trial: Selective internal radiation therapy plus Xelox, Bevacizumab and Atezolizumab in liver-dominant metastatic colorectal cancer
Randrian, V., Pernot, S., Malicot, K. L., Catena, V., Baumgaertner, I., Tacher, V., Forestier, J., Hautefeuille, V., Tabouret-Viaud, C., Gagnaire, A., et al. (2022) · Digestive and Liver Disease · doi:10.1016/j.dld.2022.04.024 · Cited by 9
A Phase I Trial of Trebananib, an Angiopoietin 1 and 2 Neutralizing Peptibody, Combined with Pembrolizumab in Patients with Advanced Ovarian and Colorectal Cancer
Huffman, B. M., Rahma, O. E., Tyan, K., Li, Y. Y., Giobbie‐Hurder, A., Schlechter, B. L., Bockorny, B., Manos, M. P., Cherniack, A. D., Bagińska, J., et al. (2024) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-23-1027 · Cited by 8
Biomarkers for immune checkpoint inhibitors in colorectal cancer: recent advances and future perspectives
Yang, C., Zhao, L., Lin, Y., Wang, S., Ye, Y., & Shen, Z. (2023) · Cancer Biology and Medicine · doi:10.20892/j.issn.2095-3941.2023.0201 · Cited by 8
Transforming the landscape of colorectal cancer treatment with immunotherapy: Evolution and future horizons
Clerick, J., Oosterwyck, A. V., & Carton, S. (2024) · Cancer Treatment and Research Communications · doi:10.1016/j.ctarc.2024.100807 · Cited by 8
Genotypic and phenotypic signatures to predict immune checkpoint blockade therapy response in patients with colorectal cancer
Zhao, X., May, A., Lou, E., & Subramanian, S. (2018) · Translational research · doi:10.1016/j.trsl.2018.02.001 · Cited by 9
High prevalence of unusual KRAS , NRAS , and BRAF mutations in POLE ‐ hypermutated colorectal cancers
Favre, L., Cohen, J., Caldéraro, J., Pécriaux, A., Nguyen, C., Bourgoin, R., Larnaudie, L., Dupuy, A., Ollier, M., Lechapt, E., et al. (2022) · Molecular Oncology · doi:10.1002/1878-0261.13257 · Cited by 8
Multiplexed Immunofluorescence Imaging Reveals an Immune-Rich Tumor Microenvironment in Mucinous Rectal Cancer Characterized by Increased Lymphocyte Infiltration and Enhanced Programmed Cell Death Protein 1 Expression
Duggan, W. P., Kısakol, B., O’Connell, E., Matveeva, A., O’Grady, T., McDonough, E. M., Lindner, A. U., McNamara, D. A., Longley, D. B., Ginty, F., et al. (2022) · Diseases of the Colon & Rectum · doi:10.1097/dcr.0000000000002624 · Cited by 7
Burden of Proof: Evaluating the Efficacy of Tumor Mutational Burden (TMB) in Predicting Response to Immune Checkpoint Inhibitors.
Newman, J. P., Seetharamu, N., & Saif, M. W. (2020) · PubMed · Cited by 7
Biomarkers to guide immunomodulatory treatment: where do we stand?
Kyriazopoulou, E., Giamarellos‐Bourboulis, E. J., & Akinosoglou, K. (2023) · Expert Review of Molecular Diagnostics · doi:10.1080/14737159.2023.2258063 · Cited by 6
Current status of immunotherapy in gastrointestinal malignancies
Lorenzen, S., Lordick, F., Loosen, S. H., Tacke, F., Trautwein, C., Roderburg, C., Ettrich, T. J., Perkhofer, L., Reinacher‐Schick, A., & Stein, A. (2020) · Zeitschrift für Gastroenterologie · doi:10.1055/a-1071-8322 · Cited by 6
A miRNA Panel Predicts Sensitivity of FGFR Inhibitor in Lung Cancer Cell Lines
Ren, S., Rivard, C. J., Yu, H., Genova, C., Rozenboom, L., Gao, D., Hinz, T. K., Rikke, B. A., Wynes, M. W., Caldwell, C. W., et al. (2018) · Clinical Lung Cancer · doi:10.1016/j.cllc.2018.06.004 · Cited by 6
Circulating Tumor DNA Response and Minimal Residual Disease Assessment in DNA Polymerase Epsilon-Mutated Colorectal Cancer Undergoing Immunotherapy
Lutfi, A., Afghan, M. K., & Kasi, P. M. (2023) · Cureus · doi:10.7759/cureus.43391 · Cited by 5
The Effect of Pembrolizumab in Absence of Programmed Death 1 Receptor
Attar, L. A., & Truong, P. V. (2018) · Cureus · doi:10.7759/cureus.2896 · Cited by 5
Predictive “omic” biomarkers of drug response: Colorectal cancer as a model
Mini, E., Landini, I., Paolo, A. D., Ravegnini, G., Saponara, S., Frosini, M., Lapucci, A., & Nobili, S. (2022) · Elsevier eBooks · doi:10.1016/b978-0-323-90190-1.00002-0 · Cited by 5
Local Therapy for Oligoprogression or Consolidation in High Mutational Burden Stage 4 Colorectal Cancer Treated With PD-1 or PD-L1 Blockade
Klemen, N. D., Court, C. M., Fernandes, M. C., Walch, H. S., Chatila, W. K., Saadat, L. V., Maron, S. B., Crane, C., Shia, J., Cercek, A., et al. (2022) · Annals of Surgical Oncology · doi:10.1245/s10434-022-12095-x · Cited by 5
Characteristics of Pan-Cancer Patients With Ultrahigh Tumor Mutation Burden
Yuan, H., Ji, J. H., Shi, M., Shi, Y., Liu, J., Wu, J., Chen, Y., Xi, W., Li, Q., Zhu, W., et al. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.682017 · Cited by 5
New approach in Understanding Colorectal Cancer Immunosuppression and Immunotherapy-Based Strategies in the Treatment of Microsatellite Stable Colorectal Cancer
Gulubova, M. V., Chonov, D. C., Ignatova, M., & Yovchev, Y. (2024) · Acta Medica Bulgarica · doi:10.2478/amb-2024-0022 · Cited by 4
Case report: Innovative treatment for one metastatic thyroid-like follicular carcinoma of the kidney with ATM and POLE mutations
Lei, J.-J., Rao, J., Feng, H., Cao, D., Yan, H., Yuan, J., Jiang, Z.-M., & Zhang, Y.-Q. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1352865 · Cited by 4
Tumor genomic alterations in severe-combined immunodeficiency bare-lymphocyte syndrome genes are associated with high mutational burden and disproportional neo-antigen rates
Wang, Y., Johnson, D. B., Lu, S., Diaz, L. A., Xu, Y., & Balko, J. M. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0584-2 · Cited by 4
Whole genome sequencing of Malaysian colorectal cancer patients reveals specific druggable somatic mutations
Yunos, R. I. M., Mutalib, N. A., Khoo, J.-S., Saidin, S., Ishak, M., Syafruddin, S. E., Tieng, F. Y. F., Yusof, N. F. M., Razak, M. R. A., Nadzir, N. M., et al. (2023) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2022.997747 · Cited by 4
Accurately estimating the length distributions of genomic micro-satellites by tumor purity deconvolution
Wang, Y., Zhang, X., Xiao, X., Zhang, F., Yan, X., Feng, X., Zhao, Z., Guan, Y., & Wang, J. (2020) · BMC Bioinformatics · doi:10.1186/s12859-020-3349-5 · Cited by 4
Precision Cancer Trials With Immunomodulatory Agents
Baretti, M., & Azad, N. S. (2019) · The Cancer Journal · doi:10.1097/ppo.0000000000000390 · Cited by 3
Advances in the synergistic and toxic attenuating effect of traditional Chinese medicine in cancer treatment
Chen, J., Dan, L., Jie, Y. A. N. G., Cai, X., Wei, G., & Cao, P. (2022) · Scientia Sinica Vitae · doi:10.1360/ssv-2021-0389 · Cited by 3
Accelerated clinical response achieved by combining short-term tumor-directed photodynamic therapy with immunotherapy-based systemic therapies in synchronous colorectal cancer with MSI-H and POLE mutation: a case report
Wang, Y., Gao, L., Ma, B., Shi, J., Yin, Z., Zhu, W., & Chen, H. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1402334 · Cited by 3
Neoadjuvant chemoradiotherapy combined with immunotherapy: a promising strategy for MSS/pMMR locally advanced rectal cancer
Yang, L. F., Tang, J., Chi, Y., Li, H., Zhang, M., Zhang, H., Ma, X., Cheng, J., & Gao, C. (2025) · Medical Oncology · doi:10.1007/s12032-025-02918-8 · Cited by 3
More than FOLFOX and FOLFIRI: The Management of Metastatic Colorectal Cancer in the Era of Precision Oncology
Jacome, A. A. D. A., & Johnson, B. (2021) · EMJ Oncology · doi:10.33590/emjoncol/21-00122 · Cited by 3
PD-1 Blockade Elicits Ongoing Remission in Two Cases of Refractory Microsatellite-Stable Cancer Harboring a POLE Mutation
Schenck, K., Masetti, M., Pfarr, N., & Lorenzen, S. (2021) · Oncology Research and Treatment · doi:10.1159/000521332 · Cited by 3
Pembrolizumab and Trastuzumab in High Tumor Mutational Burden and POLE-Mutated HER2-Positive Refractory Breast Cancer
Zhang, L., Chen, Y., Lv, Y., Jiao, S., & Zhao, W. (2022) · The Oncologist · doi:10.1093/oncolo/oyac027 · Cited by 3
DNA damage response signaling as a predictive biomarker and synergistic therapeutic target for anti‐PD‐1/PD‐L1 immunotherapy in non‐small cell lung cancer
Zhu, Z., Chen, P., & Zhao, Y. (2018) · Thoracic Cancer · doi:10.1111/1759-7714.12785 · Cited by 3
Unveiling ctDNA Response: Immune Checkpoint Blockade Therapy in a Patient with POLE Mutation-Associated Early-Onset Colon Cancer
Ramachandran, R., Cannon, M., Peshin, S., Kundranda, M. N., & Scott, A. J. (2025) · Current Oncology · doi:10.3390/curroncol32070370 · Cited by 2
Patient-derived colorectal microtumors predict response to anti-PD-1 therapy
Nguyen, D., Schaller, M. A., Terracina, K. P., Xu, X., Pedro, D. I., Pepe, A., Urueña, J. M., Dupee, Z., Diodati, N. G., Smolchek, R. A., et al. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1640500 · Cited by 2
The clinical landscape of POLE-mutant colorectal cancer: a retrospective analysis of real-world outcome
Xu, T., Zhang, X., Wang, Z., Shen, L., Wang, X., & Li, J. (2026) · BMC Medicine · doi:10.1186/s12916-025-04611-z · Cited by 2
Precision Medicine in the Era of Genetic Testing: Microsatellite Instability Evolved
Ioffe, D., McSweeny, M. J., & Hall, M. J. (2023) · Clinics in Colon and Rectal Surgery · doi:10.1055/s-0043-1770385 · Cited by 2
Advancements in immunotherapy research for colorectal cancer based on microsatellite status
Shuai, X. I. A. O., XiGuang, C. H. E. N., & XuYu, Z. U. (2023) · Scientia Sinica Vitae · doi:10.1360/ssv-2023-0103 · Cited by 2
Development and validation of a cancer-associated fibroblast gene signature-based model for predicting immunotherapy response in colon cancer
Zou, D., Xin, X., Xu, H., Xu, Y., & Xu, T. (2025) · Scientific Reports · doi:10.1038/s41598-025-01185-x · Cited by 2
Traitement des cancers colorectaux par immunothérapie : aller au-delà de MSI avec la classification moléculaire (CMS) et la charge mutationnelle
Cohen, R., Heran, M., Pudlarz, T., Hilmi, M., Tournigand, C., André, T., & Rousseau, B. (2019) · Bulletin du Cancer · doi:10.1016/j.bulcan.2018.09.008 · Cited by 2
Identification of genes and cellular response factors related to immunotherapy response in mismatch repair-proficient colorectal cancer: a bioinformatics analysis
Xue, W., & Shi, J. (2022) · Journal of Gastrointestinal Oncology · doi:10.21037/jgo-22-1070 · Cited by 2
Genomic Applications in Colorectal Carcinomas
Ritterhouse, L. L., & Samowitz, W. S. (2018) · Springer eBooks · doi:10.1007/978-3-319-96830-8_28 · Cited by 2
Landscape of Current Targeted Therapies for Advanced Colorectal Cancer
Pissarra, A. J., Abreu, C., Mansinho, A., Costa, A. L., Dâmaso, S., Lobo-Martins, S., Martins, M., & Costa, L. (2021) · IntechOpen eBooks · doi:10.5772/intechopen.93978 · Cited by 1
Immune Checkpoint Inhibitor Sensitivity of DNA Repair Deficient Tumors
Rochefort, P., Desseigne, F., Bonadona, V., Dussart, S., Coutzac, C., Sarabi, M., & de la Fouchardière, C. (2021) · Immunotherapy · doi:10.2217/imt-2021-0024 · Cited by 1
State of the art: Targeting microsatellite instability in gastrointestinal cancers
Mencel, J., Alves, A., Angelis, V., Gerlinger, M., & Starling, N. (2024) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2024.104387 · Cited by 1
Emerging role of DNA polymerase epsilon non-exonuclease domain mutations in colorectal cancer: From sequence variants to clinical implications
Xu, J.-J., Ni, C.-X., & Xu, J.-J. (2026) · World Journal of Gastroenterology · doi:10.3748/wjg.v32.i6.116028 · Cited by 1
Immune checkpoint blockade in glioma
Ferguson, S. D., Weathers, S.-P. S., & Heimberger, A. B. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-813158-9.00034-7
Advances in Immuno-oncology for the Treatment of Colorectal and Anal Cancers
Uboha, N. V., Grogan, P. T., & Deming, D. A. (2021) · Digestive Disease Interventions · doi:10.1055/s-0040-1722266
Immunotherapy for GI Cancers
Jacome, A. A. D. A., Morris, V. K., & Eng, C. (2021) · Advances in Oncology · doi:10.1016/j.yao.2021.02.024
Immunotherapy in dMMR/MSI-H Colon Cancer
Tintelnot, J., & Stein, A. (2021) · Cancer immunotherapy · doi:10.1007/13905_2021_6
Biomarkers for Immunotherapy in Gastrointestinal Cancers
Palle, J., Taı̈eb, J., & Zaanan, A. (2021) · Cancer immunotherapy · doi:10.1007/13905_2021_10
Current Treatment Landscape for Third- or Later-Line Therapy in Metastatic Colorectal Cancer
Qureshi, S., Berim, L. D., & Boland, P. M. (2021) · Current Colorectal Cancer Reports · doi:10.1007/s11888-021-00469-4
Immunology and immunotherapy in CRC
Cordero, O. J., Varela‐Calviño, R., Graña-Suárez, B., & García-López, A. (2021) · Elsevier eBooks · doi:10.1016/b978-0-323-90055-3.00031-4
Molecular genetic testing in colon cancer: clinical aspects
Martianov, A. S., Kuligina, E. S., Romanko, A. A., & Имянитов, Е. Н. (2022) · Almanac of Clinical Medicine · doi:10.18786/072-0505-2022-50-002 · Cited by 2
Immunotherapy in the Treatment of Advanced Colorectal Cancer
Raman, P., Botrus, G., & Bekaii‐Saab, T. (2022) · Cancer immunotherapy · doi:10.1007/13905_2021_12
Fluorouracil/folinic-acid/irinotecan
(2017) · Reactions Weekly · doi:10.1007/s40278-017-31197-y
Cancer Biomarkers: A Long and Tortuous Journey
Sim, W. J., Lee, K. C., & Thiery, J. P. (2022) · Springer eBooks · doi:10.1007/978-3-030-98950-7_34
The Efficacy and Plasma ctDNA as a Biomarker of Dual PD-1 and HER2 Blockade in HER2-Positive Gastric or Gastroesophageal Junction CancersPreprint
Chong, X., Bai, Y., Liu, H., Yan, Z., Cong, L., Gong, J., Wang, Y., Chen, H., Cai, J., Chen, S., et al. (2022) · SSRN Electronic Journal · doi:10.2139/ssrn.4186786
Self-citation

Authors: Gong, J., Wang, C., Lee, P. P., Chu, P., & Fakih, M.
Affiliations: Beckman Research Institute (US)
City Of Hope National Medical Center (US)
Corresponding author: Fakih, Marwan
ORCID: Gong, Jun
Wang, Chongkai
Lee, Peter P.
Fakih, Marwan
Venue: Journal of the National Comprehensive Cancer Network
Publisher: Harborside Press, LLC
Published: 2017-02
Volume: 15
Issue: 2
Pages: 142-147
ISSN: 1540-1405 (ISSN-L)
1540-1413
DOI: 10.6004/jnccn.2017.0016
OpenAlex: W2593200928
Cited by: 207
References: 15
Citations by year: 2026: 3 · 2025: 9 · 2024: 17 · 2023: 17 · 2022: 32 · 2021: 43 · 2020: 26 · 2019: 31 · 2018: 26 · 2017: 3
FWCI: 10.37
Type: journal article
Language: en
Open access: bronze
doi.org
Locations: Journal of the National Comprehensive Cancer Network (publishedVersion)
PubMed (publishedVersion)
Topics: Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
Health Sciences › Medicine › Pathology and Forensic Medicine › Genetic factors in colorectal cancer
Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
Keywords: metastatic colorectal cancer, POLE mutation, pembrolizumab, anti-PD-1 therapy, anti-PD-1 therapy response, tumor mutational burden, PD-L1 expression, treatment-refractory cancer, predictive biomarkers
MeSH terms: Poly-ADP-Ribose Binding Proteins, Adenocarcinoma, Aged, 80 and over, Antineoplastic Agents, Antineoplastic Combined Chemotherapy Protocols, Biopsy, Carcinoembryonic Antigen, Colonoscopy, DNA Mutational Analysis, DNA Polymerase II, Humans, Male, Mutation, Neoplasm Recurrence, Local, Tomography, X-Ray Computed, Colorectal Neoplasms, Lymphocytes, Tumor-Infiltrating, Proto-Oncogene Proteins p21(ras), CD8-Positive T-Lymphocytes, Microsatellite Repeats, Drug Resistance, Neoplasm, Gene Expression Profiling, High-Throughput Nucleotide Sequencing, Tumor Microenvironment, B7-H1 Antigen, Programmed Cell Death 1 Receptor, Antibodies, Monoclonal, Humanized

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Response to PD-1 Blockade in Microsatellite Stable Metastatic Colorectal Cancer Harboring a POLE Mutation

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks